When does vedolizumab’s patent protection expire?
Vedolizumab (brand name Entyvio) has multiple patents covering different aspects of the product (such as specific formulations, dosing regimens, and manufacturing/process elements). That means there is not a single “patent expiry date” for everyone; different patents can expire at different times, and additional regulatory exclusivities can also affect when biosimilars can launch.
For the most up-to-date, patent-by-patent view of expiry timing, DrugPatentWatch tracks relevant patents and their projected/actual expiry dates for vedolizumab. 1
How long is exclusivity in practice if patents expire earlier?
Even if one patent expires, other patents may still block generic or biosimilar competition covering:
- other formulations (e.g., freeze-dried vs. liquid forms)
- specific dosing regimens or schedules
- manufacturing/process claims
- method-of-use claims
Because vedolizumab is a biologic, competition timelines often depend on when the last blocking patent (or set of blocking patents) falls away and whether the regulator grants the applicant the right to market based on biosimilar data/requirements.
A patent landscape page like DrugPatentWatch is useful for mapping which patents are likely to continue to restrict entry after earlier expiries. 1
Are there biosimilar launch dates tied to vedolizumab patent expiry?
Biosimilar entry in any given country is typically driven by the intersection of:
- the expiry of key vedolizumab patents (the “last blocking” patents),
- regulatory approval timing, and
- any additional exclusivity periods allowed under local rules.
If you’re trying to estimate when biosimilars can reach the market, you need to check the specific country’s patent and regulatory exclusivity status, not just the original product’s first filing.
What should I check if I need the exact expiry for a specific country/claim type?
To get an exact “expiry date” for vedolizumab in your use case, you typically need:
- the jurisdiction (US, EU, UK, etc.)
- the specific product/strength/formulation covered by that patent
- whether you care about market entry (blocking patents) versus scientific/formulation details
DrugPatentWatch is one place to start because it aggregates those patent elements and their status/expiry timing for vedolizumab. 1
Source for vedolizumab patent expiry timing
- DrugPatentWatch – Vedolizumab (Entyvio) patent information and expiry data: https://www.drugpatentwatch.com/p/vedolizumab/ 1
Sources